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ABSTRACT
Background. Preclinical evidence has demonstrated that
common intratumor bacteria metabolize the chemothera-
peutic drug gemcitabine. The significance of this bacterial
metabolism pathway, relative to the known metabolic
pathways by host enzymes, is not known. We hypothe-
sized that bacterial metabolism is clinically significant and
that “knockdown” by antibacterial therapy has the
unintended effect of increasing the effective dose of
gemcitabine, thereby increasing the risk for gemcitabine-
associated toxicities.
Materials and Methods. We reanalyzed the comparator
arm of the MPACT trial (NCT01442974), made available
through Project Data Sphere, LLC (CEO Roundtable on
Cancer’s Life Sciences Consortium, Cary, NC; www.
projectdatasphere.org). In this arm, 430 patients with meta-
static pancreatic adenocarcinoma were treated with
gemcitabine. We used the Anderson-Gill survival model to
compare the risk of developing an adverse event after
antibacterial prescription with time unexposed to antibacte-
rials. Adverse events of grade 3 and greater were consid-
ered at three levels of granularity: all aggregated into one
endpoint, aggregated by class, and taken individually. Anti-
biotic exposures were analyzed in aggregate as well as by
class.
Results. Antibacterial exposure was associated with an
increased risk of adverse events (hazard ratio [HR]: 1.77;
confidence interval [CI]: 1.46–2.14), any hematologic adverse
event (HR: 1.64; CI: 1.26–2.13), and any gastrointestinal
adverse event (HR: 2.14; CI: 1.12–4.10) but not a constitu-
tional (HR: 1.33; CI: 0.611–2.90) or hepatologic adverse event
(HR: 0.99; CI: 0.363–2.71). Among specific adverse events,
antibacterial exposure was associated with an increased risk
of anemia (HR: 3.16; CI: 1.59–6.27), thrombocytopenia (HR:
2.52; CI: 1.31–4.85), leukopenia (HR: 3.91; CI: 1.46–10.5), and
neutropenia (HR: 1.53; CI: 1.07–2.17) but not any other spe-
cific adverse events.
Conclusion. Antibacterial exposure was associated with
an increased risk of gemcitabine-associated, dose-limiting
adverse events, including aggregate hematologic and gas-
trointestinal events, as well as four specific hematologic
adverse events, suggesting that intratumor bacteria may be
responsible for a clinically significant portion of gemcitabine
metabolism. Alternative avenues of evidence will be neces-
sary to confirm this preliminary finding and assess its gener-
alizability. There is plentiful opportunity for similar analyses
on other clinical trial data sets, where gemcitabine or other
biomimetic small molecules were used. The Oncologist
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Implications for Practice: Patients treated with gemcitabine for metastatic pancreatic ductal adenocarcinoma have an
increased rate of gemcitabine-associated toxicity during and after antibiotic therapy. This observation is consistent with pre-
clinical evidence that intratumor bacteria metabolize gemcitabine to an inactive form. Further research is needed to deter-
mine whether this observation merits any changes in clinical practice.
Correspondence: Robert W. Corty, Ph.D., School of Medicine, University of North Carolina at Chapel Hill, 120 Mason Farm Rd., Suite 5110,
Chapel Hill, North Carolina 27599, USA. Telephone: 727-480-1543; e-mail: robert_corty@med.unc.edu Received July 26, 2019; accepted
for publication February 5, 2020; published Online First on March 17, 2020. http://dx.doi.org/10.1634/theoncologist.2019-0570
No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from
the copyright holder. For information on purchasing reprints contact Commercialreprints@wiley.com. For permission information contact
permissions@wiley.com.
INTRODUCTION
Gemcitabine is a nucleoside analogue used in the treatment of
advanced pancreatic, bladder, breast, ovarian, and non-small
cell lung cancer [1]. Geller et al. recently found that bacteria
expressing the long isoform of cytidine deaminase (CDDL)
metabolize gemcitabine to its inactive form in vitro. Further-
more, they found that a mouse model of colon carcinoma
injected with CDDL-expressing bacteria could be successfully
treated with gemcitabine only when cotreated with an
antibacterial to wipe out the bacterial colonization [2]. Notably,
the bacterial family Enterobacteriaceae expresses CDDL [2],
is commonly found in the gut microbiome [3], and was found
in appreciable quantities in 30 of 65 pancreatic tumor sam-
ples sequenced [2], providing a plausible source for the
intratumor bacterial colonization via retrograde migration up
the pancreatic duct.
These results suggest a potential interaction between
gemcitabine and the host microbiome and provide a plausi-
ble biological mechanism for a clinically significant interaction
between nucleoside analogues and antibacterials that have
activity against CDDL-expressing bacteria. To date, however,
no such clinical evidence has been reported.
We hypothesized that intratumor bacteria metabolize
a clinically meaningful fraction of administered
gemcitabine. Based on this hypothesis, antibacterial ther-
apy that reduces the population of CDDL-expressing bacte-
ria was expected to increase the effective dose of
gemcitabine. We sought to test this hypothesis by
reanalyzing a clinical trial data set in which patients were
treated with gemcitabine and incidentally cotreated with
antibacterials. The possible effects of an increased dose of
gemcitabine include an increase in clinical efficacy (sur-
vival, an increase in tumor response) and an increase in
adverse events. We elected to focus our study on adverse
events because of their perceived greater sensitivity to
gemcitabine dose. Furthermore, the development of
adverse events is of immediate clinical relevance in this
population because adverse events are often dose-limiting
and it has been shown that the patients who discontinued
treatment owing to adverse events had shorter overall sur-
vival and shorter disease-free survival than patients who
continued treatment until disease progression [4].
until disease progression [7]. Baseline and demographic char-
acteristics of this population are shown in Table 1.
Over the course of the MPACT trial, physicians prescribed
antibacterials as clinically indicated. We considered patients
“exposed” from the first day of their first antibiotic prescription
until they left the trial. As a sensitivity analysis, we also consid-
ered a “temporary exposure” framework, where patients were
considered exposed only during the time period they were pre-
scribed antibiotics plus an optional lag period of 1 or 2 weeks
(supplemental online Table 2). In both frameworks, adverse
Table 1. Baseline characteristics of patients in the
comparator arm of the MPACT trial
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Peritoneum 10 (2)MATERIALS AND METHODS
We identified the comparator arm of the MPACT trial 
(NCT01442974), freely available through Project Data 
Sphere, LLS (CEO Roundtable on Cancer’s Life Sciences Con-
sortium, Cary, NC; www.projectdatasphere.org) [5, 6], as an 
appropriate data source to investigate the possible interaction 
between antibacterial exposure and gemcitabine toxicity.
Patients with metastatic pancreatic cancer were ran-
domized to receive either gemcitabine or gemcitabine plus 
nab-paclitaxel. The gemcitabine comparator arm contained 
430 patients who were treated with gemcitabine at a dose 
of 1,000 mg per square meter of body surface area weekly
for 7 of the first 8 weeks after randomization (cycle one) and 
3 of each subsequent 4 weeks (cycles two and subsequent)
gastrointestinal, constitutional, and hepatologic, and (3) each
of the 20 most common adverse events individually.
We conducted a survival analysis on pairs of (a) anti-
bacterial exposure and (b) adverse event when two criteria
were met: at least 15 adverse events were observed and at
least 5 adverse events were observed in exposed patients.
These criteria were set to ensure stability of the effect
estimates.
For the 12 pairs that met these criteria, we used the
Andersen-Gill survival model [8] to assess the association
between antibacterial exposure and the risk of developing each
adverse event. This statistical model extends the Cox propor-
tional hazards model [9] by accommodating recurrent events.
Table 2. For each of the adverse events of grade 3+ for which results are presented, the number of patients who
experienced that adverse event, the total number of experiences, and the total duration for which that adverse event was
experienced
Adverse eventa Patients, n (%) No. of events Total duration, days
Incidence rate, events
per 1,000 patient-days
Any adverse event 264 (61) 537 5108 11.5
Any hematologic 131 (30) 268 2547 5.8
Neutropenia 81 (19) 155 1403 3.3
Thrombocytopenia 29 (7) 45 354 1
Anemia 30 (7) 44 459 0.9
Neutropenia 16 (4) 30 270 0.6
Leukopenia 13 (3) 21 198 0.5
Any gastrointestinal 39 (9) 48 279 1
Abdominal pain 20 (5) 26 131 0.6
Any constitutional 28 (7) 33 354 0.7
Fatigue 19 (4) 23 271 0.5
Any hepatologic 18 (4) 21 251 0.5
AST elevated 12 (3) 14 160 0.3
A longer version of this table that includes the many adverse events for which insufficient data were available to stably estimate the effect of
antibacterial exposure is included in supplemental online Table 1.
aAdverse events were defined based on patient report and physician recording, rather than by lab values.
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Figure 1. Hazard ratio of antibacterial exposure for the development any adverse event of grade 3 or greater and each of the four most
common categories of adverse events in the comparator (gemcitabine alone) arm of the MPACT trial. Dot indicates point estimate of
hazard ratio and line indicates 95% confidence interval. In parentheses after the adverse event name, numerator is the number of occur-
rences of the adverse event during antibacterial exposure and denominator is the number of occurrences of the adverse event overall.
p values from t test. All adverse events are derived from the adverse events recorded by the investigators, not by lab values.
Abbreviations: CI, confidence interval; HR, hazard ratio.
events that started the same day as an antibiotic exposure were 
considered to have started during an unexposed time period.
We considered antibacterial exposure at two levels 
of granularity. First, we considered an aggregate “any anti-
bacterial” exposure. Second, we considered antibacterials 
separated into the most common classes used in the MPACT 
trial: quinolones, penicillins, nonpenicillin beta-lactams, and 
other.
Over the course of the MPACT trial, adverse events were 
noted at clinic visits. We considered only adverse events of 
grade 3 or greater. We considered adverse events at three 
levels of granularity: (1) an aggregate of “any adverse event,” 
(2) any one of four subgroups of adverse events: hematologic,
We included age, sex, race, and baseline performance status as
covariates to control for their effects on outcomes.
Reproducibility
All data analyzed here are freely available on Project
DataSphere, and all analysis scripts are available at https://
github.com/rcorty/gemcitabine.
RESULTS
After collapsing overlapping prescriptions, 179 patients
experienced 271 antibacterial exposure periods covering 2,588
patient-days. After collapsing overlapping adverse events,
there were 537 adverse event periods of grade 3+, of which
268 were hematologic, 48 were gastrointestinal, 33 were con-
stitutional, and 21 were hepatologic. The frequency of com-
mon specific adverse events is detailed in Table 2.
In the top-level analysis, the hazard ratio of antibacterial
exposure on “any adverse event” was at 1.77 with 95% con-
fidence interval (CI) of 1.46–2.14 and a t test p value of
1.7 × 10−9, as shown in Figure 1.
In the level two analysis, antibacterial exposure was
associated with a statistically significant increased risk of
developing hematologic (hazard ratio [HR]: 1.64; CI:
1.26–2.13; p = 2 × 10−4) and gastrointestinal (HR: 2.14;
CI: 1.12–4.1; p = .019) adverse events, but not constitu-
tional (HR: 1.33; CI: 0.61–2.9; p = .46) or hepatologic (HR:
0.99; CI: 0.36–2.71; p = .99) adverse events, as shown in
Figure 1.
In the level three analysis, antibacterial exposure was
leukopenia (HR: 3.91; CI: 1.46–10.46; p = .0056), as shown
in Figure 2. Among gastrointestinal, constitutional, and
hepatologic adverse events, antibacterial exposure was not
associated with a statistically significant increased risk of
any specific adverse event: abdominal pain (HR: 1.83; CI:
0.74–4.52; p = .18), fatigue (HR: 0.98; CI: 0.36–2.68;
p = .97), and aspartate aminotransferase elevation (HR:
1.43; CI: 0.45–4.57; p = .54).
In the antibacterial class–specific analyses, the only sta-
tistically significant associations identified were between
the quinolone class and risk of “any adverse event” (HR:
1.53; CI: 1.22–1.91; p = .001) and between the beta-lactam
class and “any hematologic event” (HR: 1.76; CI: 1.21–2.55;
p = .01; results not shown graphically).
DISCUSSION
Preclinical evidence has demonstrated that bacteria com-
monly found in the gut flora and in pancreatic ductal ade-
nocarcinoma samples can metabolize gemcitabine [2].
Whether this metabolic pathway holds any clinical signifi-
cance, however, is unknown. We addressed this question
with reanalysis of the MPACT clinical trial [7], where, in the
comparator arm, patients with advanced pancreatic cancer
were treated with gemcitabine. We reasoned that if the
microbial metabolic pathway consumes a significant frac-
tion of administered gemcitabine, patients would be
expected to experience a higher rate of gemcitabine-
associated toxicities after taking antibacterials, owing to the
decreased microbial population.
We found that after antibacterial exposure, patients have
an increased risk of developing any adverse event as well as
an increased risk of developing two classes of adverse events:
hematologic and gastrointestinal. Within the hematologic
class, we identified four specific adverse events for which
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Figure 2. Hazard ratio of antibacterial exposure for the development of specific adverse events of grade 3 or greater, grouped by
category. Dot indicates point estimate of hazard ratio and line indicates 95% confidence interval. In parentheses after the adverse
event name, numerator is the number of occurrences of the adverse event during antibacterial exposure and denominator is the
number of occurrences of the adverse event overall. p values from t test. All adverse events are derived from the adverse events
recorded by the investigators, not by lab values.
Abbreviations: CI, confidence interval; HR, hazard ratio.
associated with a statistically significant increased risk of 
developing all hematologic adverse for which hazard ratios 
were estimable: neutropenia (HR: 1.53; CI: 1.07–2.17; 
p = .017), thrombocytopenia (HR: 2.52; CI: 1.31–4.85; 
p = .005), anemia (HR: 3.16; CI: 1.59–6.27; p < .0001), and
neutropenia, thrombocytopenia, anemia, and leukopenia.
This study design and analysis cannot distinguish between
pure antibiotic toxicity and antibiotic-exacerbated gemcitabine
toxicity. However, based on known patterns of drug toxicity,
the increased risk for hematologic toxicities is most consistent
with an antibiotic-exacerbated gemcitabine toxicity and the
increased risk for gastrointestinal toxicities is most consistent
with antibiotic toxicity.
Thus, the preclinical findings of Geller et al. may be clini-
cally significant. There remain, however, notable gaps between
the two studies.
Geller et al. studied one specific bacterial species
(Escherichia coli K-12) and one specific antimicrobial
(ciprofloxacin). This study makes no observation about
any specific species of bacteria or any specific antibiotic.
These limitations are inherent in the data set analyzed.
The sample size provided little power to detect interac-
tions between individual antibiotic classes and adverse
events. The limiting factor in most cases was the number
of adverse events observed during antibiotic treatment.
Because the original study was conducted to assess clinical
outcomes, not microbiological mechanisms, no measurement
of any microbial load, diversity, or gemcitabine-metabolizing
activity was made.
Another important limitation of this study is its observa-
tional nature. The observed effect could be influenced by
potential confounding due to the patient’s overall health,
the specific illness that motivated the antibiotic prescrip-
tion, or toxicity from the antibiotic itself. We have endeav-
ored to make our analysis as robust as possible against
these concerns by adjusting for performance status, con-
ducting the analysis in both a permanent effect and tempo-
rary effect framework, considering a variety of “lags”
between exposure and effect in the temporary effect
framework (supplemental online Table 2), quantifying the
frequency of adverse events before antibiotic exposure
(supplemental online Table 3), and comparing the timing of
patient-days spent “exposed” and “unexposed” (supple-
mental online Table 4). But only a randomized trial can pro-
vide conclusive evidence and fully guard against these
potential threats to study validity.
CONCLUSION
Additional evidence to assess this hypothesis should be sought
through additional observational studies with larger sample
size, more elaborate statistical models, or additional, relevant
measurements, such as sequenced tumor samples or chemo-
therapeutic concentration. Finally, whether this effect extends
to other nucleoside analogues or other classes of chemothera-
peutics remains to be investigated.
This study provides observational clinical evidence that
patients cotreated with gemcitabine and antibiotics experi-
ence a higher effective dose of gemcitabine than patients
treated with gemcitabine alone at the same nominal dose.
Based on preclinical evidence, the hypothesized mechanism
of this effect is decreased metabolism of gemcitabine by
intratumor bacteria, possibly seeded from the gastrointesti-
nal tract.
Recent work on the effects of antibiotic treatment on
survival in patients treated with immunotherapy for mela-
noma [10] and a variety of other cancers [11] points to,
on average, an association between antibiotic exposure
and decreased survival. In the context of this rich litera-
ture of observational studies in a related clinical context,
this study suggests the possibility of an effect in the other
direction, where a cancer treatment may actually be more
effective (and more toxic) when coadministered with
antibiotics.
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